December 5, 2018

Neurimmune announces publication in Science Translational Medicine of its experimental therapy targeting misfolded SOD1

SCHLIEREN / ZURICH, SWITZERLAND – December 5, 2018 – Neurimmune announced today that preclinical data relating to its human-derived antibody targeting misfolded superoxide dismutase 1 (SOD1) have been published in the current issue of Science Translational Medicine. The paper “A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis” describes a monoclonal antibody that selectively binds to misfolded and aggregated forms of SOD1 but not to physiological SOD1. Generated by Neurimmune’s Reverse Translational MedicineTM (RTMTM) technology from human memory B cells from healthy elderly subjects, the antibody ameliorated motor symptoms and extended survival in different animal models of amyotrophic lateral sclerosis (ALS).

“We are excited about these results which provide the scientific basis for the development of a potential treatment for ALS.”, said Jan Grimm, Managing Director and CSO of Neurimmune. “In our collaboration with AL-S Pharma we are working to translate these findings into the clinic.”

Link to manuscript